Search

Your search keyword '"Bruce, Lars"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Bruce, Lars" Remove constraint Author: "Bruce, Lars"
27 results on '"Bruce, Lars"'

Search Results

1. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.

3. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial

4. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration.

7. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis

8. ILB®, a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury

10. ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis

11. ILB ® , a Low Molecular Weight Dextran Sulphate, Restores Glutamate Homeostasis, Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury.

12. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.

13. Brain volumetric deficits in MAPT mutation carriers: a multisite study

14. Low Molecular Weight Dextran Sulfate (ILB®) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat

15. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

16. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease

17. Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study

18. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers

19. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

20. Processing Electronic Medical Records : Ontology-Driven Information Extraction and Structuring in the Clinical Domain

21. Frontotemporal dementia and its subtypes: A genome-wide association study

22. Redesign of the Oz Compiler

23. FUS pathology defines the majority of tau-and TDP-43-negative frontotemporal lobar degeneration

25. ILB ® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis.

26. A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial.

27. Low Molecular Weight Dextran Sulfate (ILB ® ) Administration Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat.

Catalog

Books, media, physical & digital resources